CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

[Latest] Global Sustainable Pharmaceutical Packaging Market Size/Share Worth USD 343.01 Billion...

All Eyes on Preslie Ross: A Nationwide Supermodel Calls Florida Home...

In-Vitro Toxicology Testing Market is Poised to Attain Valuation of US$...

Marie Claire Brings Power Play Event to Atlanta

Exosomes Skincare Market to Hit USD 809.5 Mn by 2032, amid...

Momcozy Launches CoolFit Nursing Bra Series: Revolutionizing Comfort With High Elasticity...

Mass Beauty US Sales Growth Outperforms in Q1, as Prestige Remains...

TORRAS Redefines the iPhone Case Market with Ostand, OAir, and OFitness...

Wyoming Online Casinos: Super Slots Named the Best Casino Site in...

Glokore Light Therapy Face Mask Under Review: Best Wireless LED Red...

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...